NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD
11.5
-0.09 (-0.78%)
The current stock price of BLCO is 11.5 USD. In the past month the price decreased by -11.47%. In the past year, price decreased by -15.44%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 32.23 | 49.12B | ||
COO | COOPER COS INC/THE | 21.83 | 16.46B | ||
ALGN | ALIGN TECHNOLOGY INC | 19.27 | 13.16B | ||
SOLV | SOLVENTUM CORP | 10.11 | 11.70B | ||
LNTH | LANTHEUS HOLDINGS INC | 16.04 | 7.45B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 26.8 | 5.65B | ||
ICUI | ICU MEDICAL INC | 22.77 | 3.49B | ||
HAE | HAEMONETICS CORP/MASS | 15.09 | 3.21B | ||
XRAY | DENTSPLY SIRONA INC | 8.43 | 2.81B | ||
UFPT | UFP TECHNOLOGIES INC | 26.61 | 1.55B | ||
NEOG | NEOGEN CORP | 15.13 | 1.25B | ||
ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 965.30M |
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
BAUSCH + LOMB CORP
520 Applewood Crescent
Vaughan ONTARIO CA
Employees: 13300
Phone: 19082552864
The current stock price of BLCO is 11.5 USD. The price decreased by -0.78% in the last trading session.
The exchange symbol of BAUSCH + LOMB CORP is BLCO and it is listed on the New York Stock Exchange, Inc. exchange.
BLCO stock is listed on the New York Stock Exchange, Inc. exchange.
19 analysts have analysed BLCO and the average price target is 18.78 USD. This implies a price increase of 63.33% is expected in the next year compared to the current price of 11.5. Check the BAUSCH + LOMB CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BAUSCH + LOMB CORP (BLCO) has a market capitalization of 4.06B USD. This makes BLCO a Mid Cap stock.
BAUSCH + LOMB CORP (BLCO) currently has 13300 employees.
BAUSCH + LOMB CORP (BLCO) has a resistance level at 13.34. Check the full technical report for a detailed analysis of BLCO support and resistance levels.
The Revenue of BAUSCH + LOMB CORP (BLCO) is expected to grow by 4.73% in the next year. Check the estimates tab for more information on the BLCO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BLCO does not pay a dividend.
The PE ratio for BAUSCH + LOMB CORP (BLCO) is 23.96. This is based on the reported non-GAAP earnings per share of 0.48 and the current share price of 11.5 USD. Check the full fundamental report for a full analysis of the valuation metrics for BLCO.
The outstanding short interest for BAUSCH + LOMB CORP (BLCO) is 4.85% of its float. Check the ownership tab for more information on the BLCO short interest.
ChartMill assigns a fundamental rating of 3 / 10 to BLCO. BLCO has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months BLCO reported a non-GAAP Earnings per Share(EPS) of 0.48. The EPS decreased by -32.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -2.35% | ||
ROE | -4.9% | ||
Debt/Equity | 0.73 |
ChartMill assigns a Buy % Consensus number of 73% to BLCO. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 7.48% and a revenue growth 4.73% for BLCO